According to the global brokerage's analysis, Sun Pharma's key innovative products are produced in South Korea, the EU, or within the US. Therefore, Jefferies believes that the maximum tariffs on Sun Pharma's innovative products would be limited to 15%. South Korea and the EU have established pharmaceutical tariffs at 15% with the United States. Consequently, the global brokerage concluded that the highest tariffs on Sun Pharma's innovative products are likely to be limited to 15%. View full Image View full Image Sun Pharma US products ( Jefferies )Also Read | Tata Motors PV share price in focus on Monday after JLR sales rebound in Q4Sun Pharma share price On Thursday, Sun Pharma share price ended nearly 2% lower at ₹1,694.65 apiece on the BSE.

Source: Mint April 03, 2026 05:42 UTC